Health Care & Life Sciences » Pharmaceuticals | Cellectar Biosciences Inc.

Cellectar Biosciences Inc. | Ownership

Companies that own Cellectar Biosciences Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
AWM Investment Co., Inc.
106,600
2.97%
106,600
0.05%
06/30/2018
Geode Capital Management LLC
72,383
2%
72,383
0%
06/30/2018
Heights Capital Management, Inc.
49,482
1.38%
49,482
0%
12/31/2017
The Vanguard Group, Inc.
24,700
0.69%
277
0%
06/30/2018
Virtu Financial BD LLC
9,463
0.26%
9,463
0%
06/30/2018
Citadel Advisors LLC
5,630
0.16%
5,630
0%
06/30/2018
SSgA Funds Management, Inc.
5,470
0.15%
0
0%
06/30/2018
Two Sigma Securities LLC
3,255
0.09%
-384
0%
06/30/2018
Amussen, Hunsaker & Associates LLC
3,090
0.09%
1,733
0.01%
06/30/2018
Northern Trust Investments, Inc.
2,865
0.08%
0
0%
06/30/2018

About Cellectar Biosciences

View Profile
Address
100 Campus Drive
Florham Park New Jersey 07932
United States
Employees -
Website http://www.cellectar.com
Updated 07/08/2019
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.